Details of the Drug

General Information of Drug (ID: DMLW9HG)

Drug Name

Tildrakizumab

Synonyms

UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Approved	[1]

Drug Type

Antibody

Sequence

>heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADY
NEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 407 mcgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 70 mcg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.25 h [2]
Bioavailability: The bioavailability of drug is 12% [2]
Clearance: The sytemic clearance of drug is 0.32 L/day [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 23 days [3]
Metabolism: The drug is metabolized via the catabolic pathways in a manner similar to endogenous IgG [3]
Vd: The volume of distribution (Vd) of drug is 10.8 L [3]

Cross-matching ID

DrugBank ID: DB14004
TTD ID: D0FT3R

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-23 (IL23)	TTC1GLB	IL23A_HUMAN	Modulator	[1]
Interleukin-37 (IL37)	TTQTX98	IL37_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Plaque psoriasis

ICD Disease Classification

EA90.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-23 (IL23)	DTT	IL23A	5.37E-01	-0.1	-0.42

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	FDA Approved Drug Products: Orgovyx (relugolix) tablets for oral use
3	FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6	Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
8	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
9	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
10	Clinical pipeline report, company report or official report of Moderna Therapeutics.
11	Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.